The drug has demonstrated significant utility in managing type 2 diabetes and obesity, thanks to its action as a glucagon-like peptide-1 (GLP-1) receptor agonist (RA) [4,5,6]. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.